Clinical Data Lilly’s new obesity pill passes heart safety test in diabetes BioPharma DiveThe findings, which come amid FDA scrutiny of Foundayo s safety, will enable Lilly to seek a new clearance in diabetes.Clinical DataMetabolic & GLP-1Read full story pharminent April 16, 2026 (Last updated: April 16, 2026) BioPharma Dive The findings, which come amid FDA scrutiny of Foundayo s safety, will enable Lilly to seek a new clearance in diabetes. Clinical DataMetabolic & GLP-1Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly debuts more Foundayo data as FDA requests post-marketing trialsNext: FDA moves toward easing restrictions on certain peptides Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
